Chan Christopher Yi Wen, Chua Boon Yiang, Subramaniam Mythily, Suen Emily Liew Kai, Lee Jimmy
Department of General Psychiatry, Institute of Mental Health, 10 Buangkok View, Singapore 539747.
Research Division, Institute of Mental Health, 10 Buangkok View, Singapore 539747.
Pharmacogenomics. 2017 Apr;18(6):531-538. doi: 10.2217/pgs-2016-0164. Epub 2017 Mar 14.
This study aims to assess the attitudes and opinions of clinicians practicing in psychiatry toward pharmacogenomic testing, and in so doing elicits possible barriers and risks to employ this technology in patient care.
MATERIALS & METHODS: Doctors and pharmacists presently practicing in psychiatry were invited to participate in an anonymous web-based survey. Besides information on participant characteristics and experience in psychiatry, specific themes on pharmacogenomics including self-assessed competency, perceived usefulness in clinical situations, perceived risks and preferred mode of education were evaluated.
A total of 81% of respondents believed that pharmacogenomic testing would be useful for identifying suitable treatments and 71% believed that pharmacogenomic testing would be useful for medication intolerance. However, only 46.4% felt competent to order these tests. There were significant differences in responses for gender, doctors versus pharmacists and seniority in position. A total of 94.3% of respondents were concerned about costs and 84.5% were concerned about the lack of clear guidelines on its use. A total of 98.5% of respondents were keen on learning more about the applicability of pharmacogenomics, and the most preferred format of education was a lecture (44.5%).
Most clinicians acknowledge the potential of pharmacogenomic testing in clinical practice. However, concerns with regard to its cost-effectiveness and the lack of clear guidelines are possible barriers to its clinical implementation.
本研究旨在评估从事精神病学临床工作的医生对药物基因组检测的态度和看法，并借此找出在患者护理中应用该技术可能存在的障碍和风险。
邀请目前从事精神病学临床工作的医生和药剂师参与一项基于网络的匿名调查。除了收集参与者的特征信息和精神病学从业经验外，还评估了药物基因组学的特定主题，包括自我评估的能力、在临床情况下的感知有用性、感知风险以及偏好的教育方式。
共有81%的受访者认为药物基因组检测有助于确定合适的治疗方法，71%的受访者认为该检测对药物不耐受情况有用。然而，只有46.4%的人觉得自己有能力开具这些检测。在性别、医生与药剂师以及职位资历方面，回答存在显著差异。共有94.3%的受访者担心成本问题，84.5%的受访者担心缺乏关于其使用的明确指南。共有98.5%的受访者渴望更多地了解药物基因组学的适用性，最受欢迎的教育形式是讲座（44.5%）。
大多数临床医生认可药物基因组检测在临床实践中的潜力。然而，对其成本效益的担忧以及缺乏明确指南可能是其临床应用的障碍。
